1. To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults ≥ 18 years of age. 2. To assess the safety and tolerability of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age.3. To assess the reactogenicity of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age.
Emmanuel Walter, MD
Clinical and Laboratory Investigation